How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,295 results for

Sotalol

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Acute echocardiographic effects of sotalol on ventricular systolic function in dogs with ventricular arrhythmias (PubMed)

Acute echocardiographic effects of sotalol on ventricular systolic function in dogs with ventricular arrhythmias Sotalol is a commonly used antiarrhythmic drug that may alter ventricular function.To determine the effect of sotalol on echocardiographic indices of ventricular systolic function in dogs with ventricular arrhythmias.Thirty-five client-owned dogs with ventricular arrhythmias.Dogs with ventricular arrhythmias (n = 27) had an echocardiogram and 5-minute ECG performed at baseline and 2 (...) -4 hours post-sotalol (2-2.5 mg/kg PO once). Eight additional dogs underwent the same protocol but did not receive sotalol (within-day variability controls). Left ventricular (LV) internal dimension at end-systole normalized to bodyweight (LVIDs_N), LV ejection fraction (LV EF), LV shortening area, LV fractional shortening, tricuspid annular plane systolic excursion (TAPSE), and right ventricular systolic myocardial velocity were evaluated as indices of systolic function.All indices except TAPSE

Full Text available with Trip Pro

2018 Journal of Veterinary Internal Medicine

3. Efficacy and adverse effects of sotalol in adults with congenital heart disease. (PubMed)

Efficacy and adverse effects of sotalol in adults with congenital heart disease. Adults with congenital heart disease (CHD) are predisposed to arrhythmias, which can often be refractory to medical therapy. Sotalol is an attractive alternative antiarrhythmic to amiodarone in this younger patient population, given the latter's toxicity profile, but it may have proarrhythmic effects. We therefore aimed to assess the efficacy and safety of sotalol in adults with CHD.We retrospectively assessed our (...) adult CHD database for all patients ≥16 years old, with moderate to highly complex defects, who were prescribed sotalol between 2000 and 2017. Efficacy in treating the clinical arrhythmia was assessed as complete, partial or failure. Adverse effects, including proarrhythmia, were documented.Sotalol was prescribed in 82 of 902 adult CHD patients reviewed (9%). The mean age at sotalol commencement was 31.8 ± 13.1 years, with a median time on sotalol of 2.8 years. The average prescribed dose was 122 

2018 International journal of cardiology

4. Intravenous sotalol for conversion of atrial flutter in infants (PubMed)

Intravenous sotalol for conversion of atrial flutter in infants 29707488 2019 02 26 2214-0271 4 3 2018 Mar HeartRhythm case reports HeartRhythm Case Rep Intravenous sotalol for conversion of atrial flutter in infants. 117-120 10.1016/j.hrcr.2018.01.002 Aljohani Othman A OA Division of Cardiology, Department of Pediatrics, Rady Children's Hospital, University of California, San Diego, California. Perry James C JC Division of Cardiology, Department of Pediatrics, Rady Children's Hospital (...) , University of California, San Diego, California. Williams Matthew R MR Division of Cardiology, Department of Pediatrics, Rady Children's Hospital, University of California, San Diego, California. eng Case Reports 2018 01 10 United States HeartRhythm Case Rep 101656239 2214-0271 Atrial flutter IV sotalol Infantile atrial flutter Intravenous sotalol Neonatal atrial flutter 2018 5 1 6 0 2018 5 1 6 0 2018 5 1 6 1 epublish 29707488 10.1016/j.hrcr.2018.01.002 S2214-0271(18)30003-4 PMC5918188 Pediatr Cardiol

Full Text available with Trip Pro

2018 HeartRhythm Case Reports

5. Digging into Lipid Membrane Permeation for Cardiac Ion Channel Blocker d-Sotalol with All-Atom Simulations (PubMed)

Digging into Lipid Membrane Permeation for Cardiac Ion Channel Blocker d-Sotalol with All-Atom Simulations Interactions of drug molecules with lipid membranes play crucial role in their accessibility of cellular targets and can be an important predictor of their therapeutic and safety profiles. Very little is known about spatial localization of various drugs in the lipid bilayers, their active form (ionization state) or translocation rates and therefore potency to bind to different sites (...) in membrane proteins. All-atom molecular simulations may help to map drug partitioning kinetics and thermodynamics, thus providing in-depth assessment of drug lipophilicity. As a proof of principle, we evaluated extensively lipid membrane partitioning of d-sotalol, well-known blocker of a cardiac potassium channel Kv11.1 encoded by the hERG gene, with reported substantial proclivity for arrhythmogenesis. We developed the positively charged (cationic) and neutral d-sotalol models, compatible

Full Text available with Trip Pro

2018 Frontiers in pharmacology

6. Intravenous sotalol for the management of postoperative junctional ectopic tachycardia (PubMed)

Intravenous sotalol for the management of postoperative junctional ectopic tachycardia 30116712 2019 02 26 2214-0271 4 8 2018 Aug HeartRhythm case reports HeartRhythm Case Rep Intravenous sotalol for the management of postoperative junctional ectopic tachycardia. 375-377 10.1016/j.hrcr.2018.05.007 Valdés Santiago O SO Lillie Frank Abercrombie Section of Pediatric Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas. Landstrom Andrew P AP Lillie Frank Abercrombie (...) Hospital, Baylor College of Medicine, Houston, Texas. Kim Jeffrey J JJ Lillie Frank Abercrombie Section of Pediatric Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas. eng Case Reports 2018 05 30 United States HeartRhythm Case Rep 101656239 2214-0271 Arrhythmia Intravenous sotalol Junctional ectopic tachycardia Pediatrics Postoperative Sotalol 2018 02 19 2018 05 16 2018 05 23 2018 8 18 6 0 2018 8 18 6 0 2018 8 18 6 1 epublish 30116712 10.1016/j.hrcr.2018.05.007 S2214

Full Text available with Trip Pro

2018 HeartRhythm Case Reports

7. Early Experience with Intravenous Sotalol in Children with and without Congenital Heart Disease. (PubMed)

Early Experience with Intravenous Sotalol in Children with and without Congenital Heart Disease. Arrhythmias are common in the pediatric population. In patients unable to take oral medications or in need of acute therapy, options of intravenous (IV) antiarrhythmic medications are limited. Recently IV sotalol has become readily available, but experience in children is limited.The purpose of this study was to describe our initial experience with the use of IV sotalol in the pediatric population.A (...) retrospective study of all pediatric patients receiving IV sotalol was performed. Patient demographic characteristics, presence of congenital heart disease, arrhythmia type, efficacy of IV sotalol use, and adverse effects were evaluated.A total of 47 patients (26 (55%) male and 24 (51%) with congenital heart disease) received IV sotalol at a median age of 2.05 years (interquartile range 0.07-10.03 years) and a median weight of 12.8 kg (interquartile range 3.8-34.2 kg), and 13 (28%) received IV sotalol

2018 Heart Rhythm

8. Effect of sotalol on heart rate, QT interval, and atrial fibrillation cycle length in horses with atrial fibrillation (PubMed)

Effect of sotalol on heart rate, QT interval, and atrial fibrillation cycle length in horses with atrial fibrillation Based on its pharmacokinetic profile and electrophysiological effects in healthy horses, sotalol potentially could be used as a long-term PO antiarrhythmic drug in horses.To evaluate the effect of sotalol on heart rate (HR), QT interval, atrial fibrillatory rate, and success of cardioversion in horses with naturally occurring chronic atrial fibrillation (AF).Twenty-eight horses (...) referred for transvenous electrical cardioversion of AF were treated with 2 mg/kg sotalol PO q12h for 3 days before cardioversion, and 13 horses underwent the same protocol without sotalol administration.Retrospective study. Before and after sotalol or no treatment, the HR was measured at rest and during an exercise test. The QT interval and atrial fibrillation cycle length (AFCL) were measured at rest using tissue Doppler velocity imaging.In the control group, no significant differences were found

Full Text available with Trip Pro

2018 Journal of Veterinary Internal Medicine

9. Pharmacokinetics and electrophysiological effects of sotalol hydrochloride in horses. (PubMed)

Pharmacokinetics and electrophysiological effects of sotalol hydrochloride in horses. Arrhythmias in horses may require long-term anti-arrhythmic therapy. Unfortunately, oral anti-arrhythmic drugs for use in horses are currently scarce. In human patients and small animals, sotalol, a β-blocker with class III anti-arrhythmic properties, is often used for long-term treatment.To determine the pharmacokinetics of sotalol at multiple oral dosages in unfasted horses, as well as the effects on electro (...) - and echocardiographic measurements, right atrial and ventricular monophasic action potential (MAP) and effective refractory period (ERP).Placebo controlled, double-blinded experiment.Six healthy, unfasted Warmblood horses were given either 0, 2, 3 or 4 mg/kg bodyweight (bwt) sotalol orally (PO) twice daily (bid) for 9 days in a randomised cross-over design. Echocardiography and surface electrocardiography were performed and plasma concentrations of sotalol and right atrial and right ventricular MAPs and ERPs were

2018 Equine veterinary journal Controlled trial quality: uncertain

10. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation

Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

11. Pediatric Dosing of Intravenous Sotalol Based on Body Surface Area in Patients with Arrhythmia. (PubMed)

Pediatric Dosing of Intravenous Sotalol Based on Body Surface Area in Patients with Arrhythmia. In a recently published study, we evaluated the efficacy and safety of intravenous sotalol in pediatric patients with incessant tachyarrhythmias and we have found that intravenous sotalol is effective and safe. Our dosing regimen was based on the body weight of the patients. In the US, the recommendation for intravenous sotalol dosing in pediatric patients is based on body surface area (BSA) while (...) ). Each received a loading dose of 1 mg/kg intravenous sotalol administered over 10 min followed by a maintenance dose of 4.5 mg/kg/day. There was a close correlation between the sotalol loading doses calculated based on body weight and BSA across the entire age range (r = 0.977, p < 0.001). In most of the age groups, the body weight-based loading doses were lower or equal to the BSA-based doses. Only in the adolescents were the body weight-based doses higher. The maintenance doses given in our study

Full Text available with Trip Pro

2017 Pediatric Cardiology

12. Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. (PubMed)

Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. Our objective was to evaluate the efficacy and safety of intravenous (IV) sotalol in the treatment of incessant tachyarrhythmias in children with normal cardiac function. Eighty-three children admitted to hospital from October 2011 to December 2014 were treated with IV sotalol or IV sotalol plus IV propafenone. The time to conversion to sinus rhythm and maintaining sinus rhythm were evaluated. Blood (...) pressure, heart rate, QTc, PR intervals, and rhythm were monitored; 50 patients (60%) were converted to sinus rhythm with IV sotalol; time to conversion was 12.0 ± 18.0 hours; 12 additional patients (15%) were converted with IV sotalol combined with IV propafenone; time to conversion was 13.1 ± 17.6 hours. A total of 62 patients (75%) were converted. Success rates of IV sotalol for different tachycardias were similar, whereas the time to conversion differed. The time to conversion for atrioventricular

Full Text available with Trip Pro

2017 American Journal of Cardiology

13. Safety and Efficacy of Inpatient Initiation of Dofetilide versus Sotalol for atrial fibrillation (PubMed)

Safety and Efficacy of Inpatient Initiation of Dofetilide versus Sotalol for atrial fibrillation We sought to investigate and compare the safety and efficacy of two commonly used antiarrhythmic drugs, Dofetilide (DF) and Sotalol (SL), during inpatient drug initiation in patients with symptomatic atrial fibrillation (AF).We performed a single center retrospective study of consecutive patients, admitted for initiation of either DF or SL, for AF between 2012 and 2015. Rates of successful

Full Text available with Trip Pro

2017 Journal of atrial fibrillation

14. Intravenous Sotalol - Reintroducing a Forgotten Agent to the Electrophysiology Therapeutic Arsenal (PubMed)

Intravenous Sotalol - Reintroducing a Forgotten Agent to the Electrophysiology Therapeutic Arsenal Sotalol is a racemic mixture possessing beta-blocker and class III anti arrhythmic properties. Approved by US food and drug administration (FDA) since 2009 based on its bioequivalence with oral sotalol, clinicians are less familiar with the potential uses of the intravenous form despite its re-launch in United States in 2015. Available literature suggests that intravenous sotalol in recommended (...) doses can be safely administered in adult and pediatric population achieving rapid reliable therapeutic plasma concentration and without additional proarrhythmic effects when compared to its oral form as well as other antiarrhythmic medications. Intravenous sotalol may have potential uses as an alternative agent for highly symptomatic atrial fibrillation post cardiac surgery as well as in life threatening ventricular arrhythmias. As with its oral form, judicious use with close attention to QTc

Full Text available with Trip Pro

2017 Journal of atrial fibrillation

15. Use of intravenous sotalol in newborns with supraventricular tachycardia (PubMed)

Use of intravenous sotalol in newborns with supraventricular tachycardia 28748138 2019 02 26 2214-0271 3 7 2017 Jul HeartRhythm case reports HeartRhythm Case Rep Use of intravenous sotalol in newborns with supraventricular tachycardia. 332-335 10.1016/j.hrcr.2017.03.010 Kim Hannah H Division of Pediatric Cardiology, Washington University in St. Louis School of Medicine, Saint Louis, Missouri. Wolff Jennifer J Department of Pharmacy, St. Louis Children's Hospital, Saint Louis, Missouri. Dalal (...) tachycardia Intravenous sotalol Neonatal Supraventricular tachycardia 2017 7 28 6 0 2017 7 28 6 0 2017 7 28 6 1 epublish 28748138 10.1016/j.hrcr.2017.03.010 S2214-0271(17)30069-6 PMC5511985 Cardiology. 2017;136(1):52-60 27554842 Am J Cardiol. 1990 Jan 2;65(2):84A-88A 2403738 Circulation. 2010 Nov 2;122(18 Suppl 3):S729-67 20956224 Am J Cardiol. 1992 Mar 15;69(8):751-4 1546649 Acta Paediatr Scand. 1988 Jan;77(1):171 3369300 Am J Cardiol. 1990 Jan 2;65(2):12A-21A; discussion 35A-36A 2403731 Am J Cardiol

Full Text available with Trip Pro

2017 HeartRhythm Case Reports

16. Quantitative Comparison of Effects of Dofetilide, Sotalol, Quinidine, and Verapamil between Human Ex vivo Trabeculae and In silico Ventricular Models Incorporating Inter-Individual Action Potential Variability (PubMed)

Quantitative Comparison of Effects of Dofetilide, Sotalol, Quinidine, and Verapamil between Human Ex vivo Trabeculae and In silico Ventricular Models Incorporating Inter-Individual Action Potential Variability Background:In silico modeling could soon become a mainstream method of pro-arrhythmic risk assessment in drug development. However, a lack of human-specific data and appropriate modeling techniques has previously prevented quantitative comparison of drug effects between in silico models (...) and recordings from human cardiac preparations. Here, we directly compare changes in repolarization biomarkers caused by dofetilide, dl-sotalol, quinidine, and verapamil, between in silico populations of human ventricular cell models and ex vivo human ventricular trabeculae. Methods and Results:Ex vivo recordings from human ventricular trabeculae in control conditions were used to develop populations of in silico human ventricular cell models that integrated intra- and inter-individual variability in action

Full Text available with Trip Pro

2017 Frontiers in physiology

17. Sotalol

Sotalol USE OF SOTALOL IN PREGNANCY 0344 892 0909 USE OF SOTALOL IN PREGNANCY (Date of issue: March 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Sotalol is a non-selective beta-adrenoceptor blocking drug with additional class III antiarrhythmic effects. Sotalol is licensed in the UK (...) for the treatment and prophylaxis of cardiac arrhythmias, including ventricular and supraventricular tachyarrhythmias. It is not used in the treatment of hypertension. There are no studies of rates of specific pregnancy outcomes following gestational exposure to sotalol. An evidence-based assessment of the potential risks of congenital malformation, spontaneous abortion, stillbirth, intrauterine growth restriction (IUGR), preterm delivery and adverse neurodevelopmental effects following in utero exposure

2014 UK Teratology Information Service

18. Mortality risk of sotalol and amiodarone for post-CABG atrial fibrillation. (PubMed)

Mortality risk of sotalol and amiodarone for post-CABG atrial fibrillation. Sotalol and amiodarone are commonly prescribed antiarrhythmics for the treatment of post-operative atrial fibrillation (POAF). Though they are effective in maintaining sinus rhythm in this population, little is known about their association with mortality.To examine the association between sotalol and amiodarone exposure and total mortality in individuals with new-onset POAF following CABG.The computerised health (...) databases of Quebec, Canada were used to identify all patients over 65 who had undergone CABG and were newly diagnosed with POAF (January 1993 to June 2003). A time-matched nested-case-control approach was used to compare current users of sotalol and amiodarone with those not exposed to either medication during the same period. Rate ratios of mortality were estimated using conditional logistic regression.4770 eligible patients were identified (930 cases, 4648 matched controls). Sotalol users had fewer

2016 International journal of cardiology

19. Sotalol versus Amiodarone in Treatment of Atrial Fibrillation (PubMed)

Sotalol versus Amiodarone in Treatment of Atrial Fibrillation The availability of intravenous (IV) Sotalol has equalized the treatment options since both amiodarone and sotalol are available in both IV and oral formulations. A review of the efficacy of sotalol as compared to amiodarone both for conversion of atrial fibrillation (AF) and maintenance of normal sinus rhythm (NSR) following cardiac surgery was undertaken. Standard methods of meta-analysis were employed. Full text publications (...) of clinical trials written in English that compared the efficacy of sotalol to amiodarone were included in the analysis. For the conversion of AF to NSR, five studies were found eligible for the analysis. Two studies clinically compared sotalol to amiodarone for the maintenance of NSR after cardiac surgery. The common relative success of sotalol was 0.947 (95Cl: 0.837 to 1.071, P = 0.385), revealing essentially no differences in efficacy for conversion between amiodarone and sotalol. The average

Full Text available with Trip Pro

2016 Journal of atrial fibrillation

20. Sotalol

Sotalol Sotalol Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Sotalol Sotalol Aka: Sotalol , Betapace From Related Chapters II (...) ) These images are a random sampling from a Bing search on the term "Sotalol." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Cost: Medications Sotalol HCL (on 6/18/2017 at ) #30 tablets for $4.00 $0.13 each #90 tablets for $10.00 $0.11 each sotalol (on 5/17/2017 at ) SOTALOL 120 MG TABLET Generic $0.14 each SOTALOL 160 MG TABLET Generic $0.16 each SOTALOL 80 MG TABLET Generic $0.09 each SOTALOL AF 120 MG TABLET Generic $0.14 each

2018 FP Notebook

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>